Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: A subgroup analysis of a double-blind, randomized, multicenter, Italian study

Vincenzo Tullo, Gianni Allais, Marcella Curone, Michel D. Ferrari, Stefano Omboni, Chiara Benedetto, Bruno Colombo, Dario Zava, Gennaro Bussone

Research output: Contribution to journalArticle

Abstract

Migraine with aura affects ~20-30 % of migraineurs and it is much less common than migraine without aura. The aim of this study was to compare the efficacy of frovatriptan 2.5 mg and zolmitriptan 2.5 mg in the treatment of migraine with aura. Analysis was carried out in a subset of 18 subjects with migraine with aura (HIS criteria) out of the 107 enrolled in a multicenter, randomized, double-blind, cross-over study. According to the study design, each patient had to treat three episodes of migraine in no more than 3 months with one drug, before switching to the other treatment. The rate of pain-free episodes at 2 h was significantly (p

Original languageEnglish
JournalNeurological Sciences
Volume33
Issue numberSUPPL. 1
DOIs
Publication statusPublished - May 2012

Keywords

  • Frovatriptan
  • Migraine with aura
  • Zolmitriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Fingerprint Dive into the research topics of 'Frovatriptan versus zolmitriptan for the acute treatment of migraine with aura: A subgroup analysis of a double-blind, randomized, multicenter, Italian study'. Together they form a unique fingerprint.

  • Cite this